CCJ vs NXE: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CCJ and NXE share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CCJ and NXE exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Cameco (CCJ) is one of the world's largest publicly traded uranium producers and a major supplier of nuclear fuel. Based in Saskatchewan, Canada, it mines uranium from some of the highest-grade deposits in the world, including the Cigar Lake and McArthur River operations, and sells uranium concentrate (U3O8) to utilities that run nuclear power plants. Beyond mining, Cameco participates across the nuclear fuel cycle through refining, conversion, and fuel-fabrication activities, and it holds a significant interest in Westinghouse, a leading provider of nuclear reactor technology and services, acquired alongside Brookfield. Cameco's revenue is tied to long-term contracts with utilities and to uranium spot and contract prices, which are driven by global nuclear power demand, supply discipline, and the broader case for clean, baseload electricity. It trades on the New York Stock Exchange and the Toronto Stock Exchange.

Full CCJ guide

NexGen Energy (NXE) is a Canadian uranium development company advancing the Rook I project in the Athabasca Basin of Saskatchewan, one of the highest-grade uranium districts in the world. Its flagship Arrow deposit is among the largest undeveloped high-grade uranium resources globally. NexGen is a pre-production developer: it is working through permitting, federal and provincial environmental approvals, and project financing toward a construction decision, rather than mining and selling uranium today. The investment case is leveraged to the price of uranium and to the company successfully permitting, financing, and building a large mine on schedule and on budget. NexGen is dual-listed, trading on the New York Stock Exchange and the Toronto Stock Exchange, and is followed closely by investors betting on a nuclear-energy and uranium-supply revival. Because it does not yet generate meaningful revenue from production, it carries the elevated risk profile typical of a single-asset mining developer.

Full NXE guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• CCJ drivers: Nuclear demand and the clean-energy case; Uranium supply discipline and pricing.
• NXE drivers: World-class Athabasca asset; Nuclear revival and uranium demand.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Cameco's results are tied to volatile uranium prices and to global nuclear power sentiment, which can swing on policy and on high-profile events. For NXE, nexGen is pre-revenue and depends on a single project, so it carries concentrated development risk: permitting delays, cost overruns, construction execution, and the need to raise large amounts of capital, which can dilute existing shareholders.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick CCJ if you believe its drivers more; NXE if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CCJ and NXE guides.

CCJ. Cameco trades on a very high multiple of current earnings (about 139 times trailing and 45 times forward as of October 16, 2026) because the market is valuing its long-term uranium contract book and Westinghouse stake rather than one year of lumpy profits. Analysts' consensus calls for EPS to rise from about C$1.45 in 2026 to about C$2.60 in 2027; the mean analyst target of about $128 sits well above the $82.04 close. The balance sheet is light, with about C$1.1 billion of cash against C$1.2 billion of debt.

NXE. As a pre-production developer, NexGen cannot be valued on current earnings: trailing and forward P/E are negative and meaningless, and reported quarterly results swing between profit and loss on non-operating items. The market prices it on Rook I's expected economics, the uranium price and the odds the 2030 schedule holds, and in 2026 it has priced that lower, with the stock down ~18% year to date despite early works finishing. Figures are approximate as of mid-October 2026 and should be verified against the latest filings and technical reports.

Headline figures (approximate, October 2026): CCJ shows revenue (ttm) ~C$3.5 billion, revenue growth (q2 2026, yoy) ~-7%, net income (ttm) ~C$355 million, operating margin (ttm) ~9%; NXE shows stage Pre-production; site-preparation construction license and financing in place, first ore targeted for Q3 2030, revenue (ttm) None from production, net income (ttm) ~-$254 million loss; quarters swing on non-operating items (Q1 2026 ~-$156 million, Q2 2026 ~+$75 million); Q2 EPS ~-$0.04 vs ~-$0.05 consensus, cash and debt ~$970 million cash against ~$619 million debt (debt to equity ~34%); trailing free cash flow ~-$298 million.

CCJ and NXE are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CCJ and NXE exposure against your real portfolio. It is not an investment adviser.